Thomas J Scriba

Summary

Affiliation: University of Cape Town
Country: South Africa

Publications

  1. pmc Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG
    Michele Tameris
    South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine IIDMM and School of Child and Adolescent Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester, Western Cape 6850, South Africa
    Tuberculosis (Edinb) 93:143-9. 2013
  2. pmc A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 185:769-78. 2012
  3. pmc Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Observatory, South Africa
    J Immunol 180:1962-70. 2008
  4. ncbi request reprint Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, South Africa
    J Infect Dis 203:1832-43. 2011
  5. pmc Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    Eur J Immunol 40:279-90. 2010
  6. pmc Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function
    One B Dintwe
    South African Tuberculosis Vaccine Initiative and School of Child and Adolescent Health, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Eur J Immunol 43:2409-20. 2013
  7. pmc CD4 and CD8 T-cell responses to mycobacterial antigens in African children
    Nontobeko G Tena-Coki
    Institute of Infectious Diseases and Molecular Medicine, South African Tuberculosis Vaccine Initiative, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 182:120-9. 2010
  8. pmc Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns
    Andreia P Soares
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    J Infect Dis 207:1084-94. 2013
  9. pmc Relationship between chemokine receptor expression, chemokine levels and HIV-1 replication in the lungs of persons exposed to Mycobacterium tuberculosis
    Barbara Kalsdorf
    Clinical Infectious Diseases Research Initiative, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa
    Eur J Immunol 43:540-9. 2013
  10. pmc Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns
    Benjamin M N Kagina
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 182:1073-9. 2010

Collaborators

Detail Information

Publications26

  1. pmc Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG
    Michele Tameris
    South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine IIDMM and School of Child and Adolescent Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester, Western Cape 6850, South Africa
    Tuberculosis (Edinb) 93:143-9. 2013
    ..A phase IIb trial of a candidate vaccine, MVA85A, was conducted in a high burden setting in South Africa to evaluate proof-of-concept efficacy for prevention of TB in infants...
  2. pmc A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 185:769-78. 2012
    ..Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control...
  3. pmc Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Observatory, South Africa
    J Immunol 180:1962-70. 2008
    ..IL-17- and IL-22-producing CD4(+) T cells may play important roles in the human immune response to mycobacteria...
  4. ncbi request reprint Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, South Africa
    J Infect Dis 203:1832-43. 2011
    ..We assessed the safety of and characterized the T cell response induced by 3 doses of the candidate vaccine, MVA85A, in BCG-vaccinated infants from a setting where tuberculosis is endemic...
  5. pmc Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    Eur J Immunol 40:279-90. 2010
    ..This includes induction of novel Th1-cell populations that have not been previously described in humans...
  6. pmc Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function
    One B Dintwe
    South African Tuberculosis Vaccine Initiative and School of Child and Adolescent Health, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Eur J Immunol 43:2409-20. 2013
    ..Importantly, surface phenotypes commonly used as proxies for memory T-cell function did not associate with functional effects of vaccination. ..
  7. pmc CD4 and CD8 T-cell responses to mycobacterial antigens in African children
    Nontobeko G Tena-Coki
    Institute of Infectious Diseases and Molecular Medicine, South African Tuberculosis Vaccine Initiative, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 182:120-9. 2010
    ..Furthermore, more efficacious TB vaccines are needed for children with immunodeficiencies such as HIV infection, who are at highest risk of disease...
  8. pmc Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns
    Andreia P Soares
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    J Infect Dis 207:1084-94. 2013
    ..Furthermore, the functional and phenotypic attributes of BCG-induced long-lived memory T-cell responses remain unclear...
  9. pmc Relationship between chemokine receptor expression, chemokine levels and HIV-1 replication in the lungs of persons exposed to Mycobacterium tuberculosis
    Barbara Kalsdorf
    Clinical Infectious Diseases Research Initiative, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa
    Eur J Immunol 43:540-9. 2013
    ..tuberculosis infection of BAL cells ex vivo change RANTES expression. These data suggest ongoing HIV-1 replication predominantly drives local pulmonary CCR5(+) T-cell activation in HIV/latent M. tuberculosis co-infection...
  10. pmc Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns
    Benjamin M N Kagina
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 182:1073-9. 2010
    ..Immunogenicity of new tuberculosis (TB) vaccines is commonly assessed by measuring the frequency and cytokine expression profile of T cells...
  11. pmc Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation
    Andreia Soares
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    J Immunol Methods 362:43-50. 2010
    ..Overall our data suggest that intracellular Ki67 expression provides a specific, quantitative and reproducible measure of antigen-specific T cell proliferation in vitro...
  12. pmc HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine
    Nazma Mansoor
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    J Infect Dis 199:982-90. 2009
    ..Information regarding the immunogenicity of BCG is imperative for the risk/benefit assessment of BCG vaccination in HIV-infected infants; however, no such data exist...
  13. pmc Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease
    Lerisa Govender
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, South Africa
    Vaccine 29:51-7. 2010
    ..Persons with LTBI preferentially recognize Rv2659 and Rv2660, compared with patients with TB disease. These results suggest promise of these antigens for incorporation into post-exposure TB vaccines...
  14. pmc Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response
    Benjamin M N Kagina
    South African Tuberculosis Vaccine Initiative SATVI, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Vaccine 27:5488-95. 2009
    ..The neonatal immune system is immature. Our hypothesis was that delaying BCG vaccination from birth to 10 weeks of age would enhance the vaccine-induced immune response...
  15. pmc Significantly skewed memory CD8+ T cell subsets in HIV-1 infected infants during the first year of life
    Nazma Mansoor
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Anzio Road, Observatory, 7925, South Africa
    Clin Immunol 130:280-9. 2009
    ..We concluded that the proportion of naive, memory, effector and senescent CD8(+) T cells during the first year of life is significantly altered by HIV-1 infection...
  16. pmc HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria
    Barbara Kalsdorf
    Clinical Infectious Diseases Research Initiative, University of Cape Town, Observatory, South Africa
    Am J Respir Crit Care Med 180:1262-70. 2009
    ..Immune responses in the lung are important to restrict the growth of M. tuberculosis to prevent the development of disease...
  17. ncbi request reprint Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
    Michele D Tameris
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Lancet 381:1021-8. 2013
    ..We aimed to assess safety, immunogenicity, and efficacy of MVA85A against tuberculosis and Mycobacterium tuberculosis infection in infants...
  18. pmc Maturation of innate responses to mycobacteria over the first nine months of life
    Muki S Shey
    South African Tuberculosis Vaccine Initiative and School of Child and Adolescent Health, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa
    J Immunol 192:4833-43. 2014
    ....
  19. pmc Optimization of a whole blood intracellular cytokine assay for measuring innate cell responses to mycobacteria
    Muki S Shey
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    J Immunol Methods 376:79-88. 2012
    ..This assay may be applied to the study of innate cell responses to any GFP-expressing pathogen, and can be performed on blood volumes as low as 200 μL per condition, making the assay particularly suitable for pediatric studies...
  20. pmc Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa
    Tony Hawkridge
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    J Infect Dis 198:544-52. 2008
    ..We investigated the safety and immunogenicity of MVA85A in mycobacteria-exposed--but Mycobacterium tuberculosis-uninfected--healthy adults from a region of South Africa where TB is endemic...
  21. pmc The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
    Michele Tameris
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    PLoS ONE 9:e87340. 2014
    ..We determined if a MVA85A viral-vector boost could enhance the durability of mycobacteria-specific T cell responses above those induced by BCG alone...
  22. pmc Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis
    Kerryn Matthews
    Clinical Infectious Diseases Research Initiative, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Observatory 7925, South Africa
    Tuberculosis (Edinb) 91:587-93. 2011
    ..We propose that our findings support a role for IL-22 in TB-induced pathology or the resulting repair process...
  23. pmc Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles
    Andreia P Soares
    South African TB Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, Vaccine Initiative, University of Cape Town, Cape Town, South Africa
    J Immunol 180:3569-77. 2008
    ..Measuring IFN-gamma production alone underestimates the magnitude and complexity of the host cytokine response to BCG vaccination and may not be an optimal readout in studies of BCG and novel tuberculosis vaccination...
  24. ncbi request reprint Immunological protection against tuberculosis
    Willem A Hanekom
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town
    S Afr Med J 97:973-7. 2007
  25. ncbi request reprint Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART
    Rebecca Sutherland
    MRC Human Immunology Unit, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ, UK
    AIDS 20:821-9. 2006
    ..To determine whether long-term HAART in chronic HIV-1 infection restores fully functional Mycobacterium tuberculosis (MTB)-specific CD4 T-cell responses...
  26. ncbi request reprint Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining
    Thomas J Scriba
    The Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
    J Immunol 175:6334-43. 2005
    ..These cells would not be detectable with normal flow-cytometric techniques...